Veos Pharmaceuticals is a science-driven cleantech and biotech company developing nature-based solutions for soil regeneration, water purification, and emissions reduction. Our flagship platform, OliQuell™, upcycles olive waste into a mineral-enhanced formulation that reduces CH₄ and H₂S emissions, improves oxygenation, and removes heavy metals and agrochemical residues from water systems.
Headquartered in Madrid and profitable since 2024, Veos Pharma is a MassChallenge finalist and active in collaborations with PepsiCo, Bayer, Syngenta, UPL and leading EU innovation platforms. We hold IP across the EU, US, and Canada, with full regulatory clearance for use in agriculture and wastewater.
We are seeking consortium partners across Horizon Europe and RIV-Circular to scale impact in circular bioeconomy, industrial decarbonization, and climate-smart agri-waste applications.
Dr. Bassam Damaj is a biotech entrepreneur and pharmaceutical innovator with over 25 years of experience building science-based ventures.
He has founded 7 companies, led 3 IPOs, and raised over $500M across the U.S., EU, and MENA.
As CEO of Veos Pharmaceuticals, he leads the development of ThymoTropin™, the first natural and clinically validated myostatin regulator, designed to combat sarcopenia by preserving muscle growth, strength, and endurance in aging populations.
His expertise spans biotechnology, functional ingredients, clinical development, and global strategic partnerships — with a focus on healthy aging and longevity.